
    
      The objective of the present study is a comparison of treatment of patients with newly
      diagnosed glioblastoma multiforme grade IV. Patients will be randomized in one of two arms
      when included. Patients randomly assigned to arm A will receive Nimotuzumab (OSAG 101) plus
      Temozolomide concomitant with standard radiotherapy. Patients randomised in arm B will
      receive standard radiotherapy plus Temozolomide treatment.
    
  